Skip to main content

Advertisement

Contact Nancy Tich

From: A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome

Contact corresponding author